-
2024-513724-42-00
10
Medulloblastoma
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517295-37-00
5
low and intermediate risk neuroblastoma
-
2024-518013-25-00
4
Idiopathic Pulmonary Fibrosis
-
2025-521038-27-00
5
Immune system diseases
-
2025-522692-29-00
4
Subacute Moderate to Severe Traumatic Brain Injury (TBI)
-
2025-523259-72-00
5
Hidradenitis Suppurativa (HS)
-
2025-523389-26-00
5
Relapsed/refractory primary central nervous system lymphoma
-
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-523544-12-00
5
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-523576-23-00
5
Unresectable Stage III non-small cell lung cancer without progression
-
2025-524078-40-00
5
Chronic Spontaneous Urticaria
-
2025-525005-20-00
6
Male Infertility
-
2026-525640-14-00
6
Candidemia
-
2025-523180-38-00
4
2026-05-21
Uncontrolled Moderate to Severe Eosinophilic Asthma
-
2024-514754-79-00
4
2026-05-06
Pulmonary Arterial Hypertension (PAH)
-
2025-523230-77-00
4
2026-04-27
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
-
2024-520353-21-00
3
2026-02-24
Myeloproliferative Neoplasms
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-521299-76-00
7
2025-12-18
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
-
2024-520209-38-00
5
2025-09-19
Obesity or Overweight
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer